IL115849A0 - Tangential filtration preparation of liposomal drugs and liposome product thereof - Google Patents

Tangential filtration preparation of liposomal drugs and liposome product thereof

Info

Publication number
IL115849A0
IL115849A0 IL11584995A IL11584995A IL115849A0 IL 115849 A0 IL115849 A0 IL 115849A0 IL 11584995 A IL11584995 A IL 11584995A IL 11584995 A IL11584995 A IL 11584995A IL 115849 A0 IL115849 A0 IL 115849A0
Authority
IL
Israel
Prior art keywords
tangential filtration
liposome product
liposomal drugs
filtration preparation
preparation
Prior art date
Application number
IL11584995A
Original Assignee
Merz & Co Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz & Co Gmbh & Co filed Critical Merz & Co Gmbh & Co
Publication of IL115849A0 publication Critical patent/IL115849A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
IL11584995A 1994-11-03 1995-11-02 Tangential filtration preparation of liposomal drugs and liposome product thereof IL115849A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33379094A 1994-11-03 1994-11-03

Publications (1)

Publication Number Publication Date
IL115849A0 true IL115849A0 (en) 1996-01-31

Family

ID=23304261

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11584995A IL115849A0 (en) 1994-11-03 1995-11-02 Tangential filtration preparation of liposomal drugs and liposome product thereof

Country Status (2)

Country Link
IL (1) IL115849A0 (en)
WO (1) WO1996014057A1 (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
WO1999013865A1 (en) 1997-09-18 1999-03-25 Depotech Corporation Sustained-release liposomal anesthetic compositions
ES2384094T3 (en) * 1997-11-14 2012-06-29 Pacira Pharmaceuticals, Inc. Production of multivesicular liposomes
GB2417727B (en) 2003-06-13 2008-01-16 Alnylam Europe Ag Double-stranded ribonucleic acid with increased effectiveness in an organism
ES2515092T3 (en) 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator and methods of improving sleep quality and treating depression
JP5070038B2 (en) 2004-02-24 2012-11-07 ザ ジェネラル ホスピタル コーポレーション Catalytic radiofluorination
EP1750776A2 (en) 2004-04-30 2007-02-14 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a c5-modified pyrimidine
NZ552183A (en) 2004-06-17 2009-10-30 Infinity Discovery Inc Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
WO2006124726A2 (en) 2005-05-12 2006-11-23 The General Hospital Corporation Novel biotinylated compositions
US8377971B2 (en) 2006-08-03 2013-02-19 Trustees Of Tufts College Non-flushing niacin analogues, and methods of use thereof
EP2065058A1 (en) 2007-11-28 2009-06-03 Koninklijke Philips Electronics N.V. Non-spherical contrast agents for CEST MRI based on bulk magnetic susceptibility effect
EP2067485A1 (en) 2007-12-07 2009-06-10 Koninklijke Philips Electronics N.V. Drug carrier providing MRI contrast enhancement
US9492417B2 (en) 2008-08-21 2016-11-15 The Johns Hopkins University Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
SI3133160T1 (en) 2008-10-24 2019-05-31 Sarepta Therapeutics, Inc. Exon skipping compositions for dmd
CA2753975C (en) 2009-03-02 2017-09-26 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
EP2305216A1 (en) 2009-09-25 2011-04-06 Koninklijke Philips Electronics N.V. Two step ultrasound protocol for drug delivery
US8697858B2 (en) 2009-11-13 2014-04-15 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating influenza viral infection
EP2545173A2 (en) 2010-03-12 2013-01-16 Sarepta Therapeutics, Inc. Antisense modulation of nuclear hormone receptors
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
US20130260460A1 (en) 2010-04-22 2013-10-03 Isis Pharmaceuticals Inc Conformationally restricted dinucleotide monomers and oligonucleotides
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US9238042B2 (en) 2010-05-13 2016-01-19 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
EP2585072A4 (en) 2010-06-24 2013-12-25 Tufts College Niacin mimetics, and methods of use thereof
WO2011163612A1 (en) 2010-06-24 2011-12-29 Trustees Of Tufts College Niacin mimetics, and methods of use thereof
EP2407157A1 (en) 2010-07-13 2012-01-18 Koninklijke Philips Electronics N.V. Lipid bilayer carrier for drugs or imaging agents
US20130302253A1 (en) 2011-01-28 2013-11-14 Koninklijke Philips N.V. Carriers for the local release of hydrophilic prodrugs
EP2535326A1 (en) 2011-06-16 2012-12-19 Koninklijke Philips Electronics N.V. Novel lipidomimetic compounds and uses thereof
CA2840215A1 (en) 2011-06-22 2012-12-27 Abhijit S. BAPAT Conjugate-based antifungal and antibacterial prodrugs
EP2732035A2 (en) 2011-07-15 2014-05-21 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
ES2935606T3 (en) 2011-12-08 2023-03-08 Sarepta Therapeutics Inc Oligonucleotide Analogs Targeting Human LMNA
EA201491259A1 (en) 2011-12-23 2014-11-28 Новартис Аг COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF BCL2 WITH BOND PARTNERS
WO2013096060A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
US20140357666A1 (en) 2011-12-23 2014-12-04 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
WO2013096059A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
AU2012355613A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
AP3613A (en) 2012-05-15 2016-02-29 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 abl1abl2 bcr-abl1
PL2900637T3 (en) 2012-05-15 2018-01-31 Novartis Ag Thiazole or imidazole substituted pyrimidine, pyridine and pyrazine amide derivatives and related compounds as abl1, abl2 and bcr-abl1 inhibitors for the treatment of cancer, specific viral infections and specific cns disorders
EP2861576B1 (en) 2012-05-15 2018-01-10 Novartis AG Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
CA2871332A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
AU2013274101B2 (en) 2012-06-15 2017-09-07 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
JP6431480B2 (en) 2012-08-31 2018-11-28 ザ ジェネラル ホスピタル コーポレイション Biotin conjugates for the treatment and diagnosis of Alzheimer's disease
CN111440796A (en) 2012-12-20 2020-07-24 萨雷普塔医疗公司 Improved exon skipping compositions for the treatment of muscular dystrophy
MA38325B1 (en) 2013-02-19 2019-03-29 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degradation agents
ES2762881T3 (en) 2013-03-14 2020-05-26 Sarepta Therapeutics Inc Exon skipping compositions for the treatment of muscular dystrophy
PT2970964T (en) 2013-03-14 2019-03-14 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy
CA2906812A1 (en) 2013-03-15 2014-09-18 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy
CA2915357C (en) 2013-06-14 2023-10-03 Invictus Oncology Pvt. Ltd. Lipid-based platinum compounds and nanoparticles
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
WO2015107494A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
ES2699351T3 (en) 2014-01-17 2019-02-08 Novartis Ag Derivatives of 1-pyridazin / triazin-3-yl-piper (-azine) / idine / pyrolidine and compositions thereof to inhibit the activity of SHP2
JO3517B1 (en) 2014-01-17 2020-07-05 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
CN113559105A (en) 2014-01-29 2021-10-29 维奥姆治疗有限公司 Treatment of resistant acne
HUE042283T2 (en) 2014-03-12 2019-06-28 Nippon Shinyaku Co Ltd Antisense nucleic acid
KR20160132496A (en) 2014-04-03 2016-11-18 인빅터스 온콜로지 피비티. 엘티디. Supramolecular combinatorial therapeutics
WO2016100716A1 (en) 2014-12-18 2016-06-23 Vasant Jadhav Reversirtm compounds
ES2918385T3 (en) 2015-05-19 2022-07-15 Akamara Therapeutics Inc Process for the preparation of supramolecular compounds based on platinum
EP3303286B1 (en) 2015-06-01 2023-10-04 Cedars-Sinai Medical Center Compounds that bind to rela of nf-kb for use in treating cancer
US10975080B2 (en) 2015-06-19 2021-04-13 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
ES2824576T3 (en) 2015-06-19 2021-05-12 Novartis Ag Compounds and compositions to inhibit SHP2 activity
CN112625028A (en) 2015-06-19 2021-04-09 诺华股份有限公司 Compounds and compositions for inhibiting SHP2 activity
UY36851A (en) 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS
JP2018529715A (en) 2015-09-30 2018-10-11 サレプタ セラピューティクス， インコーポレイテッド Methods for treating muscular dystrophy
EP3362458A1 (en) 2015-10-16 2018-08-22 Invictus Oncology Pvt. Ltd. Fluorescent anticancer platinum drugs
WO2017079563A1 (en) 2015-11-06 2017-05-11 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
WO2017190041A1 (en) 2016-04-29 2017-11-02 Sarepta Therapeutics, Inc. Oligonucleotide analogues targeting human lmna
SI3452465T1 (en) 2016-05-04 2021-04-30 Genoscience Pharma Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
ES2810852T3 (en) 2016-06-14 2021-03-09 Novartis Ag Compounds and compositions to inhibit shp2 activity
WO2018005805A1 (en) 2016-06-30 2018-01-04 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
JP7160807B2 (en) 2016-12-19 2022-10-25 サレプタ セラピューティクス， インコーポレイテッド Exon-skipping oligomeric conjugates for muscular dystrophy
SG10202012839TA (en) 2016-12-19 2021-01-28 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
LT3554554T (en) 2016-12-19 2022-11-25 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP3612215A4 (en) 2017-04-20 2021-05-26 aTyr Pharma, Inc. Compositions and methods for treating lung inflammation
EA201991450A1 (en) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY
US20200248178A1 (en) 2017-09-28 2020-08-06 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
WO2019067979A1 (en) 2017-09-28 2019-04-04 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
US20210145852A1 (en) 2017-09-28 2021-05-20 Sarepta Therapeutics, Inc. Combination Therapies for Treating Muscular Dystrophy
US10765760B2 (en) 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP4219717A3 (en) 2018-06-13 2023-12-20 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
TW202020153A (en) 2018-07-27 2020-06-01 美商薩羅塔治療公司 Exon skipping oligomers for muscular dystrophy
EP3620164A1 (en) 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
BR112021011018A2 (en) 2018-12-13 2021-08-31 Sarepta Therapeutics, Inc. EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
US20220168261A1 (en) 2019-02-14 2022-06-02 Akamara Therapeutics, Inc. Compounds and methods for managing cancer through immune system
EP3946376A1 (en) 2019-03-28 2022-02-09 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy with casimersen
EP3955966A1 (en) 2019-04-18 2022-02-23 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
WO2020257489A1 (en) 2019-06-19 2020-12-24 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
IL294271A (en) 2019-12-26 2022-08-01 Nippon Shinyaku Co Ltd Antisense nucleic acid that induces skipping of exon 50
CA3173049A1 (en) 2020-02-28 2021-09-02 Nippon Shinyaku Co., Ltd. Antisense nucleic acid inducing skipping of exon 51
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
WO2023178230A1 (en) 2022-03-17 2023-09-21 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer conjugates
WO2024073570A1 (en) 2022-09-28 2024-04-04 Altos Labs, Inc. Expression of regeneration factors in aged/senescent cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2877160B2 (en) * 1987-07-29 1999-03-31 ザ リポソーム カンパニー，インコーポレイテッド Separation method by particle size
US5314695A (en) * 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
EP0565665B1 (en) * 1991-10-04 1998-03-04 Dade International Inc. Preparation of prothrombin time reagents from recombinant human tissue factor and synthetic phospholipids

Also Published As

Publication number Publication date
WO1996014057A1 (en) 1996-05-17

Similar Documents

Publication Publication Date Title
IL115849A0 (en) Tangential filtration preparation of liposomal drugs and liposome product thereof
GB2313310B (en) Local delivery and monitoring of drugs
AU4990397A (en) Compound-loaded liposomes and methods for their preparation
PL322624A1 (en) Skin care composition containing retinoides and liposomes
AU2002301268A1 (en) Production of multivesicular liposomes
PL313386A1 (en) Novel pearls ensuring controllable drug release and pharmaceutic preparation containing them
EP0863748A4 (en) Liposomal compositions and methods of using them
SK63795A3 (en) Metallocene catalytic synthesis method of their preparation and use
EP0750910A4 (en) Liposome preparation
IL118469A (en) Naphthalene derivatives their preparation and intermediates thereof
ZA967654B (en) Electrodes and methods of preparation thereof
HUP0001266A3 (en) Lipid complexes and liposomes of highly insoluble platinum complexes
ZA986437B (en) Derivatives of acyl-piperazinyl-pyrimidines their preparation and application as medicaments
ZA956915B (en) Glycinamide derivatives processes for their preparation and medicines containing them
EP0748327A4 (en) Structure of a novel lipid a and methods utilizing same
PL319588A1 (en) Lyophilisate of a lipid complex of water-insoluble campotectins
ZA984266B (en) Pharmaceutical composition and process of preparation
IL126247A0 (en) Novel imidazolidine derivatives their preparation their use and pharmaceutical preparations comprising them
AU4981896A (en) Liposome composition and method for administering liposome-loadable drugs
NZ300198A (en) Preparation of n-arylhydroxylamines and n-hetarylhydroxylamines
AU7428691A (en) Long-acting liposome peptide pharmaceutical products and processes for the preparation thereof
IL123322A0 (en) Tetrahydroquinolines their preparation and pharmaceutical compositions containing them
IL113811A0 (en) Preparation of 9-amino camptothecin
IL117078A0 (en) Substituted benzenesulfonylureas and -thioureas processes for their preparation their use for the production of pharmaceutical preparations and pharmaceutical preparations containing them
IL113135A0 (en) Liposomes and suspensions thereof comprising multilamellar liposomes